⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410168 | 0.74 | — | — | |
| SCHEMBL22055533 | 0.74 | MEN1 (0.36) | — | |
| SCHEMBL2986066 | 0.72 | — | — | |
| SCHEMBL1535168 | 0.72 | — | — | |
| SCHEMBL13999056 | 0.72 | — | — | |
| SCHEMBL12301379 | 0.72 | — | — | |
| SCHEMBL1492553 | 0.72 | — | — | |
| SCHEMBL19454563 | 0.72 | — | — | |
| SCHEMBL19453390 | 0.72 | MEN1 (0.36) | — | |
| SCHEMBL482203 | 0.72 | MEN1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-2895488-B1 | TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-115335364-B | 5-Haloalkoxy-pyrimidine compounds as herbicides | 先正达农作物保护股份公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2024022365-A1 | WNT PATHWAY INHIBITOR COMPOUND | 杭州阿诺生物医药科技有限公司 | 2024-02-01 | — | — | WO | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396482-A | Wnt pathway inhibitor compound | 杭州阿诺生物医药科技有限公司 | 2024-01-12 | — | — | CN | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| CN-101616586-A | The heterocyclic receptor agonists of treatment diabetes and metabolic disorder | METABOLEX INC | 2009-12-30 | — | — | CN | disclosed |
| US-7638541-B2 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. | 2009-10-29 | — | — | US | disclosed |
| EP-2111107-A2 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | Metabolex Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009123992-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008083238-A2 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-4410530-A | CARDIO-SELECTIVE B-RECEPTOR BLOCKING AGENTS AND STIMULANTS | CIBA-GEIGY CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| US-4195090-A | ADRENERGIC BLOCKING AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-03-25 | — | — | US | disclosed |
| US-4115575-A | CARDIOVASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |